The Modern Commercialization of Science is a Passel of Ponzi Schemes

Social Epistemology

Volumn 26, Issue 3-4, 2012, Pages 285-310

  Mirowski, Philip ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Biotechnology; Commercial Bibliometrics; Commercialization of Science; Technology Transfer

Indexed keywords

EID: 84871271339     PISSN: 02691728     EISSN: 14645297     Source Type: Journal    
DOI: 10.1080/02691728.2012.697210     Document Type: Article

References (63)

1. Adams James. 2007. Recent trends in US science and engineering. In Perspectives on US competitiveness in science and technology, edited by Titus Galama and James Hosek, pp. 37-48. Santa Monica: Rand Corporation. Available from www.rand.org/pubs/conf_proceedings/2007/RAND_CF235.pdf; INTERNET.
2. Adelman, David E. and DeAngelis, Kathryn L. 2007. Patent metrics: The mismeasure of innovation in the biotech patent debate. Texas Law Review, 85: 1677-1744.
3. Aggarwal, Saurabh. 2007. What's fueling the biotech engine?. Nature Biotechnology, 25(10): 1097-1104.
4. Akerlof, George and Shiller, Robert. 2009. Animal spirits, Princeton, NJ: Princeton University Press.
5. Angell, Marcia. 2004. The truth about the drug companies: How they deceive us and what to do about it, New York: Random House.
6. Berman, Elizabeth. 2008. Why did universities start patenting?. Social Studies of Science, 38(6): 835-872.
7. Berman, Elizabeth. 2011. Creating the Market University: how academic science became an economic engine, Princeton, NJ: Princeton University Press.
8. Blumenstyk, Goldie. 2010. Despite recession, universities report rock solid performance in commercializing inventions. Chronicle of Higher Education, 17 December.
9. Booth, Bruce. 2007. When less is more. Nature Biotechnology, 25(8): 853-857.
10. Buckley, Ted. 2007. The myth of the anticommons. White paper. Available from www.bio.org; INTERNET.
11. Caulfield, Timothy, Cook-Deegan, Robert M., Scott Kieff, F. and Walsh, John P. 2006. Evidence and anecdotes: An analysis of human gene patenting. Nature Biotechnology, 24(9): 1091-1094.
12. Chan, Sewell, and Jo McGinty. 2010. Fed papers show breadth of emergency measures. New York Times, 1 December.
13. Chancellor, Edward. 2007. Ponzi nation. Institutional Investor, 7 February. Available from http://www.institutionalinvestor.com/Article/1234217/Ponzi-Nation.html; INTERNET.
14. Cockburn, Iain, and Josh Lerner. 2009. The cost of capital for early-stage biotechnology ventures. Available from http://www.analysisgroup.com/article.aspx?id=8646; INTERNET.
15. Coriat, Benjamin, Dumoulin, Jérôme, Flori, Yves-Antoine, Barnett, Tony, Souteyrand, Yves and Moatti, Jean-Paul. 2003. "Patents, generic drugs and the markets for antiretrovirals". In Economics of AIDS and access to HIV-AIDS care in developing countries: issues and challenges, Edited by: Moatti, Jean-Paul, Barnett, Tony, Coriat, Benjamin, Souteyrand, Yves, Dumoulin, Jérome and Flori, Yves-Antoine. 27-37. France: Agence nationale de recherches sur le SIDA.
16. Dasgupta, Partha and David, Paul A. 1994. Toward a new economics of science. Policy Research, 23(5): 487-521.
17. David, Paul A. 2006. Europe's universities and innovation-Past, present and future. SIEPR Discussion Paper No. 0610, Stanford Institute for Economic Policy Research.
18. Dewan, Sheila. 2009. Despite odds, cities race to bet on Biotech. New York Times, 11 June.
19. Engel, Kathleen and McCoy, Patricia. 2011. The subprime virus: Reckless credit, regulatory failure, and next steps, Oxford: Oxford University Press.
20. Ferguson, Charles. 2012. Predator nation, New York: Crown.
21. Galbraith, James. 2008. The predator state. How conservatives abandoned the free market and why liberals should too, New York: Free Press.
22. Geiger, Roger and Sá, Creso. 2008. Tapping the riches of science. Universities and the promise of economic growth, Cambridge, MA: Harvard University Press.
23. Gottinger, Hans-Werner, and Celia L. Umali. 2008. Strategic alliances in global biotech pharma industries. The Open Business Journal 1: 10-24.
24. Greenberg, Daniel. 2007. Science for sale: The perils, rewards, and delusions of campus capitalism, Chicago: University of Chicago Press.
25. Guess Andy. 2007. American science plateau. Inside Higher Education, 20 July. Available from www.insidehighered.com; INTERNET.
26. Hicks, Diana. 2007. "Global research competition affects U.S. output". In Science and the university, Edited by: Stephan, P. E. and Ehrenberg, R. G. 232-242. Madison: University of Wisconsin Press.
27. Hill, Derek, Rapoport, Alan, Lehming, Rolf and Bell, Robert. 2007. Changing US output of scientific articles 1988-2003, Arlington, VA: NSF Division of Science Resource Statistics.
28. Hopkins, Michael, Martin, Paul A., Nightingale, Paul, Kraft, Alison and Mahdi, Surya. 2007. The myth of the biotech revolution: An assessment of technological, clinical and organisational change. Research Policy, 36(4): 566-589.
29. Inside Job. 2010. Directed by Charles H. Ferguson. Sony Pictures Classics.
30. Jaffe, Adam and Lerner, Josh. 2004. Innovation and its discontents, Princeton, NJ: Princeton University Press.
31. Kaiser, David. 2002. Scientific manpower, cold war requisitions, and the production of American physicists after World War II. Historical Studies in the Physical and Biological Sciences, 33: 131-159.
32. Kaiser, David. 2004. The postwar suburbanization of American physics. American Quarterly, 56(4): 851-888.
33. Kaiser, David. 2006. The physics of spin: Sputnik politics and American physicists in the 1950s. Social Research, 73: 1225-1252.
34. Kaiser, David. 2008. Toil, trouble, and the cold war bubble: Physics and the academy since World War II. Available from http://pirsa.org/08090000; INTERNET.
35. Lewis, Michael. 2010. The big short: Inside the doomsday machine, New York: Norton.
36. Jeffrey, Mervis. 2007. US output flattens, NSF wonders why. Science, 317(5838): 582
37. Minsky, Hyman. 2008. Stabilizing the unstable economy, New York: McGraw Hill.
38. Mirowski, Philip. 2010a. Inherent vice. Markomata microfoundations for Minsky's crisis theory. Journal of Institutionalist Economics, 6: 415-443.
39. Mirowski, Philip. 2010b. The great mortification: Economists' responses to the crisis of 2007- (and counting). Hedgehog Review, 12(2): 28-42.
40. Mirowski, Philip. 2011. ScienceMart™: Privatizing American science, Cambridge, MA: Harvard University Press.
41. Mirowski, Philip and Plehwe, Dieter, eds. 2009. The road from Mont Pèlerin: The making of the neoliberal thought collective, Cambridge, MA: Harvard University Press.
42. Mirowski, Philip and Sent, Esther-Mirjam. 2007. "The commercialization of science and the response of STS". In Handbook of science, technology and society studies, Edited by: Hackett, Ed, Amsterdamska, Olga and Lynch, Michael. 635-689. Cambridge, MA: MIT Press.
43. Nakamoto, Michio, and David Wighton. 2007. Bullish Citigroup is still dancing. Financial Times, 10 July.
44. National Science Board. 2008a. Science and engineering indicators 2008, Arlington, VA: National Science Foundation.
45. National Science Board. 2008b. Research and development: Essential foundation for US competitiveness in a global economy, Arlington, VA: National Science Foundation.
46. Newfield, Christopher. 2008. Unmaking the public university: The forty-year assault on the middle class, Cambridge, MA: Harvard University Press.
47. Nightingale, Paul and Martin, Paul. 2004. The myth of the biotech revolution. Trends in Biotechnology, 22(11): 564-569.
48. Pear, Robert. 2008. Patent law battle a boon for lobbyists. New York Times, 30 April. Available from http://www.nytimes.com/2008/04/30/business/30patent.html; INTERNET.
49. Pisano, Gary P. 2006. Science business: The promise, the reality, and the future of biotech, Cambridge, MA: Harvard Business School Press.
50. Pollack, Andrew. 2008. For Biotech, a tax break spells hope. New York Times, 10 December.
51. Powell, Walter, Jason Owen-Smith, and Jeannette A. Colyvas. 2007. Innovation and emulation: Lessons from the experiences of U.S. universities in selling private rights to public knowledge. Minerva 45 (2): 121-42.
52. PricewaterhouseCoopers. 2009. Biotech reinvented: Where do you go from here? Available from http://www.pwc.com/gx/en/pharma-life-sciences/forms/biotech-reinvented.jhtml; INTERNET.
53. Rasmussen, Nicholas. 1997. The midcentury biophysics bubble. History of Science, 35: 245-293.
54. Reinhart, Carmen and Rogoff, Kenneth. 2009. This time is different: Eight centuries of financial folly, Princeton, NJ: Princeton University Press.
55. Robbins-Roth, Cynthia. 2000. From alchemy to IPO: The business of biotechnology, New York: Basic Books.
56. Shapin, Steven. 2008. The scientific life: A moral history of a late modern vocation, Chicago: University of Chicago Press.
57. Shapin, Steven. 2011. Commerce at the helm?. Science, 331(6013): 33
58. Smith, Yves. 2010. ECONned: How unenlightened self interest undermined democracy and corrupted capitalism, New York: Palgrave.
59. Stiglitz, Joseph. 2010. Freefall: America, free markets, and the sinking of the world economy, New York: Norton.
60. Taibbi, Matt. 2010. Griftopia: Bubble machines, vampire squids, and the long con that is breaking America, New York: Spiegel and Grau.
61. Tyfield, David. 2012. The economics of science. A critical realist overview, London: Routledge.
62. Woolgar, Steve. 2004. Marketing ideas. Economy and Society, 33(4): 448-462.
63. Zuckoff, Mitchell. 2005. Ponzi's scheme: The true story of a financial legend, New York: Random House.